| NCT03030248 |
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients |
https://ClinicalTrials.gov/show/NCT03030248 |
Recruiting |
Medical College of Wisconsin |
2020-06-30 |
| NCT03388268 |
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment |
https://ClinicalTrials.gov/show/NCT03388268 |
Active, not recruiting |
Washington University School of Medicine |
2020-12-31 |
| NCT03824795 |
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD |
https://ClinicalTrials.gov/show/NCT03824795 |
Completed |
MGB Biopharma Limited |
2020-04-03 |
| NCT03268213 |
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis |
https://ClinicalTrials.gov/show/NCT03268213 |
Active, not recruiting |
Stony Brook University |
2022-06-30 |
| NCT03200093 |
Oral Vancomycin for Preventing Clostridium Difficile Recurrence |
https://ClinicalTrials.gov/show/NCT03200093 |
Enrolling by invitation |
Rochester General Hospital |
2020-06-30 |
| NCT03183141 |
ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03183141 |
Enrolling by invitation |
Seres Therapeutics, Inc. |
2020-02-29 |
| NCT03183128 |
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03183128 |
Active, not recruiting |
Seres Therapeutics, Inc. |
2020-07-31 |
| NCT03182907 |
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) |
https://ClinicalTrials.gov/show/NCT03182907 |
Recruiting |
Merck Sharp & Dohme Corp. |
2022-05-09 |
| NCT03110133 |
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff |
https://ClinicalTrials.gov/show/NCT03110133 |
Active, not recruiting |
Finch Research and Development LLC. |
2020-02-28 |
| NCT03107169 |
Treatment of Initial Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03107169 |
Completed |
Universidad Autonoma de Nuevo Leon |
2015-09-30 |
| NCT03106844 |
The ICON Study: Outcomes After FMT for Patients With IBD and CDI |
https://ClinicalTrials.gov/show/NCT03106844 |
Recruiting |
Brigham and Women’s Hospital |
2020-06-30 |
| NCT03005379 |
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) |
https://ClinicalTrials.gov/show/NCT03005379 |
Active, not recruiting |
VA Office of Research and Development |
2022-05-30 |
| NCT02996487 |
Screening to Prophylax Against Clostridium Difficile Infection - |
https://ClinicalTrials.gov/show/NCT02996487 |
Recruiting |
William Beaumont Hospitals |
2020-09-30 |
| NCT02981316 |
Treatment of Recurrent Clostridium Difficile Infection With RBX7455 |
https://ClinicalTrials.gov/show/NCT02981316 |
Active, not recruiting |
Mayo Clinic |
2020-11-30 |
| NCT02951702 |
Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics |
https://ClinicalTrials.gov/show/NCT02951702 |
Completed |
St. Luke’s Hospital, Chesterfield, Missouri |
2017-05-31 |
| NCT02865616 |
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT02865616 |
Recruiting |
NuBiyota |
2019-12-15 |
| NCT02857582 |
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile |
https://ClinicalTrials.gov/show/NCT02857582 |
Completed |
Uppsala University |
2018-10-31 |
| NCT02784002 |
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT02784002 |
Completed |
Summit Therapeutics |
2016-08-31 |
| NCT02743234 |
Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02743234 |
Completed |
University of Aarhus |
2019-02-28 |
| NCT02725437 |
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults |
https://ClinicalTrials.gov/show/NCT02725437 |
Completed |
Pfizer |
2017-02-28 |
| NCT02692651 |
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections |
https://ClinicalTrials.gov/show/NCT02692651 |
Recruiting |
University of Michigan |
2021-01-31 |
| NCT02592343 |
A Prospective Trial of Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02592343 |
Active, not recruiting |
McMaster University |
2020-01-31 |
| NCT02589847 |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02589847 |
Completed |
Rebiotix Inc. |
2017-06-30 |
| NCT03595566 |
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03595566 |
Recruiting |
Summit Therapeutics |
2021-06-30 |
| NCT02570477 |
FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment |
https://ClinicalTrials.gov/show/NCT02570477 |
Active, not recruiting |
Chinese University of Hong Kong |
2018-01-31 |
| NCT02134392 |
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection |
https://ClinicalTrials.gov/show/NCT02134392 |
Recruiting |
Nationwide Children’s Hospital |
2022-01-31 |
| NCT02563106 |
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI |
https://ClinicalTrials.gov/show/NCT02563106 |
Completed |
Synthetic Biologics Inc. |
2016-11-30 |
| NCT02561195 |
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years |
https://ClinicalTrials.gov/show/NCT02561195 |
Completed |
Pfizer |
2017-03-07 |
| NCT02502682 |
Chlorhexidine Bathing Effect on Clostridium Difficile Rates |
https://ClinicalTrials.gov/show/NCT02502682 |
Completed |
Northwestern Medicine |
2016-06-30 |
| NCT02465463 |
Early FMT for C.Difficile |
https://ClinicalTrials.gov/show/NCT02465463 |
Completed |
Emory University |
2016-11-30 |
| NCT02440438 |
Host Immune Response to Clostridium Difficile Infection (ICD) |
https://ClinicalTrials.gov/show/NCT02440438 |
Completed |
Hospices Civils de Lyon |
2016-08-31 |
| NCT02437591 |
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT02437591 |
Completed |
Astellas Pharma Inc |
2016-05-12 |
| NCT02437487 |
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) |
https://ClinicalTrials.gov/show/NCT02437487 |
Completed |
Seres Therapeutics, Inc. |
2016-07-31 |
| NCT02423967 |
Fresh Versus Frozen Stool for Fecal Transplant in Children |
https://ClinicalTrials.gov/show/NCT02423967 |
Completed |
Mayo Clinic |
2019-03-04 |
| NCT02395848 |
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection |
https://ClinicalTrials.gov/show/NCT02395848 |
Recruiting |
McMaster University |
2021-12-31 |
| NCT02316470 |
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study |
https://ClinicalTrials.gov/show/NCT02316470 |
Completed |
Valneva Austria GmbH |
2015-05-31 |
| NCT02301000 |
IMT for Primary Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02301000 |
Active, not recruiting |
Oslo University Hospital |
2020-10-31 |
| NCT02299570 |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02299570 |
Completed |
Rebiotix Inc. |
2016-01-31 |
| NCT02269150 |
Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02269150 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-10-31 |
| NCT02255305 |
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI |
https://ClinicalTrials.gov/show/NCT02255305 |
Recruiting |
NorthShore University HealthSystem |
2019-09-30 |
| NCT02254967 |
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population |
https://ClinicalTrials.gov/show/NCT02254967 |
Completed |
Astellas Pharma Inc |
2016-03-27 |
| NCT02218372 |
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT02218372 |
Completed |
Astellas Pharma Inc |
2018-03-07 |
| NCT02179658 |
A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT02179658 |
Completed |
Astellas Pharma Inc |
2016-09-08 |
| NCT02127814 |
Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile |
https://ClinicalTrials.gov/show/NCT02127814 |
Completed |
Case Western Reserve University |
2014-08-31 |
| NCT02127398 |
Stool Transplants to Treat Refractory Clostridium Difficile Colitis |
https://ClinicalTrials.gov/show/NCT02127398 |
Recruiting |
Duke University |
2022-05-31 |
| NCT02117570 |
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. |
https://ClinicalTrials.gov/show/NCT02117570 |
Completed |
Pfizer |
2015-12-31 |
| NCT02106338 |
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. |
https://ClinicalTrials.gov/show/NCT02106338 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-12-31 |
| NCT02092935 |
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) |
https://ClinicalTrials.gov/show/NCT02092935 |
Completed |
Summit Therapeutics |
2015-10-31 |
| NCT01296386 |
An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 |
https://ClinicalTrials.gov/show/NCT01296386 |
Completed |
Valneva Austria GmbH |
2013-04-30 |
| NCT01295918 |
Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children |
https://ClinicalTrials.gov/show/NCT01295918 |
Completed |
St Marina University Hospital, Varna, Bulgaria |
2013-06-30 |
| NCT02053181 |
Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT02053181 |
Completed |
Actelion |
2012-09-30 |
| NCT02052726 |
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine. |
https://ClinicalTrials.gov/show/NCT02052726 |
Completed |
Pfizer |
2015-05-02 |
| NCT03353506 |
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection |
https://ClinicalTrials.gov/show/NCT03353506 |
Completed |
University of Alberta |
2019-06-05 |
| NCT01946750 |
Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections |
https://ClinicalTrials.gov/show/NCT01946750 |
Completed |
Versailles Hospital |
2016-06-30 |
| NCT01925417 |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea |
https://ClinicalTrials.gov/show/NCT01925417 |
Completed |
Rebiotix Inc. |
2014-03-31 |
| NCT01914731 |
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum |
https://ClinicalTrials.gov/show/NCT01914731 |
Completed |
Massachusetts General Hospital |
2014-10-31 |
| NCT01901276 |
Effects of Gastric Acid on Colonic Microbiome |
https://ClinicalTrials.gov/show/NCT01901276 |
Completed |
Columbia University |
2015-03-31 |
| NCT01822977 |
The Impact of Proton Pump Inhibitors on the Fecal Microbiome |
https://ClinicalTrials.gov/show/NCT01822977 |
Completed |
Mayo Clinic |
2013-12-31 |
| NCT01818141 |
Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin |
https://ClinicalTrials.gov/show/NCT01818141 |
Completed |
Hartford Hospital |
2014-12-15 |
| NCT01716533 |
Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT01716533 |
Completed |
GlaxoSmithKline |
2015-06-01 |
| NCT01706367 |
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years |
https://ClinicalTrials.gov/show/NCT01706367 |
Completed |
Pfizer |
2014-01-31 |
| NCT01704937 |
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum |
https://ClinicalTrials.gov/show/NCT01704937 |
Completed |
Massachusetts General Hospital |
2014-05-31 |
| NCT01691248 |
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) |
https://ClinicalTrials.gov/show/NCT01691248 |
Completed |
Optimer Pharmaceuticals LLC |
2015-03-18 |
| NCT01680874 |
Probiotics for Clostridium Difficile Infection in Older Adults |
https://ClinicalTrials.gov/show/NCT01680874 |
Completed |
University of Wisconsin, Madison |
2015-02-28 |
| NCT01670149 |
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea |
https://ClinicalTrials.gov/show/NCT01670149 |
Completed |
University of Nottingham |
2016-07-31 |
| NCT01598311 |
A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) |
https://ClinicalTrials.gov/show/NCT01598311 |
Completed |
Cubist Pharmaceuticals LLC |
2015-07-26 |
| NCT01597505 |
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) |
https://ClinicalTrials.gov/show/NCT01597505 |
Completed |
Cubist Pharmaceuticals LLC |
2015-03-20 |
| NCT01591863 |
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT01591863 |
Completed |
Optimer Pharmaceuticals LLC |
2014-03-07 |
| NCT03349268 |
Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection |
https://ClinicalTrials.gov/show/NCT03349268 |
Recruiting |
University of Michigan |
2022-05-31 |
| NCT01513239 |
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) |
https://ClinicalTrials.gov/show/NCT01513239 |
Completed |
Merck Sharp & Dohme Corp. |
2015-05-22 |
| NCT01401023 |
Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT01401023 |
Completed |
Michigan State University |
2013-07-31 |
| NCT01398969 |
Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI |
https://ClinicalTrials.gov/show/NCT01398969 |
Completed |
McMaster University |
2015-01-31 |
| NCT04247542 |
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
https://ClinicalTrials.gov/show/NCT04247542 |
Recruiting |
Acurx Pharmaceuticals LLC |
2021-07-31 |
| NCT04090346 |
Fecal Microbiota Transplant |
https://ClinicalTrials.gov/show/NCT04090346 |
Enrolling by invitation |
Methodist Health System |
2024-06-30 |
| NCT04014413 |
Safety and Efficacy of Fecal Microbiota Transplantation |
https://ClinicalTrials.gov/show/NCT04014413 |
Recruiting |
Chinese University of Hong Kong |
2023-10-31 |
| NCT04003818 |
Efficacy and Safety of Teicoplanin in CDAD |
https://ClinicalTrials.gov/show/NCT04003818 |
Recruiting |
Sanofi |
2022-04-30 |
| NCT04000555 |
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT04000555 |
Recruiting |
University of South Florida |
2020-06-30 |
| NCT03988855 |
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03988855 |
Recruiting |
Deinove |
2020-06-05 |
| NCT03973697 |
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03973697 |
Active, not recruiting |
University of Pennsylvania |
2021-07-31 |
| NCT03970200 |
PMT for Severe-CDI |
https://ClinicalTrials.gov/show/NCT03970200 |
Active, not recruiting |
University of Pennsylvania |
2021-07-31 |
| NCT03931941 |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) |
https://ClinicalTrials.gov/show/NCT03931941 |
Recruiting |
Rebiotix Inc. |
2020-04-30 |
| NCT03925636 |
Specific Carbohydrate Diet for Clostridium Difficile |
https://ClinicalTrials.gov/show/NCT03925636 |
Recruiting |
Seattle Children’s Hospital |
2022-01-01 |
| NCT03918629 |
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study |
https://ClinicalTrials.gov/show/NCT03918629 |
Recruiting |
Pfizer |
2020-06-09 |
| NCT03880539 |
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03880539 |
Recruiting |
University of Kansas Medical Center |
2020-09-30 |
| NCT03857464 |
C Difficile Near-patient Diagnostics |
https://ClinicalTrials.gov/show/NCT03857464 |
Recruiting |
University of Calgary |
2020-02-15 |
| NCT03834038 |
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03834038 |
Active, not recruiting |
Vancouver Island Health Authority |
2019-06-30 |
| NCT03829475 |
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI |
https://ClinicalTrials.gov/show/NCT03829475 |
Recruiting |
Brigham and Women’s Hospital |
2021-06-01 |
| NCT03827447 |
Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile |
https://ClinicalTrials.gov/show/NCT03827447 |
Recruiting |
Medical College of Wisconsin |
2021-06-01 |
| NCT03806803 |
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection |
https://ClinicalTrials.gov/show/NCT03806803 |
Recruiting |
University of Alberta |
2021-03-31 |
| NCT03804736 |
Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03804736 |
Active, not recruiting |
Universidad Autonoma de Nuevo Leon |
2018-06-30 |
| NCT03796650 |
Fecal Transplantation for Primary Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03796650 |
Recruiting |
Oslo University Hospital |
2024-01-31 |
| NCT03788434 |
Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03788434 |
Recruiting |
Vedanta Biosciences, Inc. |
2020-12-31 |
| NCT03778606 |
Oligosaccharide for Cdiff(+) Heme-onc Patients |
https://ClinicalTrials.gov/show/NCT03778606 |
Recruiting |
Medical College of Wisconsin |
2020-06-01 |
| NCT03760484 |
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03760484 |
Recruiting |
University of Alberta |
2021-12-16 |
| NCT03710694 |
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT03710694 |
Completed |
Da Volterra |
2019-08-09 |
| NCT03617172 |
PROCLAIM – Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol |
https://ClinicalTrials.gov/show/NCT03617172 |
Recruiting |
Vanderbilt University Medical Center |
2022-11-30 |
| NCT03579459 |
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age |
https://ClinicalTrials.gov/show/NCT03579459 |
Completed |
Pfizer |
2019-08-06 |
| NCT03562741 |
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile |
https://ClinicalTrials.gov/show/NCT03562741 |
Recruiting |
University of Massachusetts, Worcester |
2022-01-16 |
| NCT03548051 |
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) |
https://ClinicalTrials.gov/show/NCT03548051 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-09-06 |
| NCT03497806 |
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03497806 |
Enrolling by invitation |
Finch Research and Development LLC. |
2020-02-01 |
| NCT03466502 |
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics |
https://ClinicalTrials.gov/show/NCT03466502 |
Enrolling by invitation |
University of Nevada, Reno |
2020-03-31 |
| NCT03462459 |
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03462459 |
Recruiting |
University of Wisconsin, Madison |
2021-12-31 |
| NCT03427229 |
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03427229 |
Completed |
Catholic University of the Sacred Heart |
2017-10-30 |
| NCT01259726 |
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT01259726 |
Completed |
Shire |
2013-06-30 |
| NCT01241552 |
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) |
https://ClinicalTrials.gov/show/NCT01241552 |
Completed |
Merck Sharp & Dohme Corp. |
2014-12-09 |
| NCT01232595 |
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections |
https://ClinicalTrials.gov/show/NCT01232595 |
Completed |
Novartis |
2013-07-31 |
| NCT01230957 |
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults |
https://ClinicalTrials.gov/show/NCT01230957 |
Completed |
Sanofi |
2012-11-30 |
| NCT01222702 |
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT01222702 |
Completed |
Actelion |
2012-10-16 |
| NCT01087892 |
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT01087892 |
Completed |
University of Sussex |
2013-09-30 |
| NCT01085591 |
Study of CB-183,315 in Participants With Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT01085591 |
Completed |
Cubist Pharmaceuticals LLC |
2011-04-13 |
| NCT00958308 |
Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection |
https://ClinicalTrials.gov/show/NCT00958308 |
Completed |
Bio-K Plus International Inc. |
2009-03-31 |
| NCT04012788 |
CDI Synbiotic Study |
https://ClinicalTrials.gov/show/NCT04012788 |
Recruiting |
Hvidovre University Hospital |
2020-05-01 |
| NCT01987895 |
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT01987895 |
Completed |
Actelion |
2017-02-26 |
| NCT01983683 |
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea |
https://ClinicalTrials.gov/show/NCT01983683 |
Completed |
Actelion |
2017-03-09 |
| NCT01896830 |
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan |
https://ClinicalTrials.gov/show/NCT01896830 |
Completed |
Sanofi |
2013-10-31 |
| NCT04026009 |
Study of GlaxoSmithKline’s (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years |
https://ClinicalTrials.gov/show/NCT04026009 |
Recruiting |
GlaxoSmithKline |
2021-07-13 |
| NCT03244644 |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) |
https://ClinicalTrials.gov/show/NCT03244644 |
Active, not recruiting |
Rebiotix Inc. |
2020-06-30 |
| NCT03090191 |
Clostridium Difficile Vaccine Efficacy Trial |
https://ClinicalTrials.gov/show/NCT03090191 |
Active, not recruiting |
Pfizer |
2020-09-28 |
| NCT03595553 |
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03595553 |
Recruiting |
Summit Therapeutics |
2021-06-30 |
| NCT01905709 |
Fecal Microbiota Transplantation for C Diff Infection |
https://ClinicalTrials.gov/show/NCT01905709 |
Recruiting |
Englewood Hospital and Medical Center |
2020-07-31 |
| NCT04121169 |
Treatment of Mild-moderate Clostridium Difficile Infection (CDI) |
https://ClinicalTrials.gov/show/NCT04121169 |
Recruiting |
ImmuniMed Inc. |
2020-09-30 |
| NCT02968758 |
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains |
https://ClinicalTrials.gov/show/NCT02968758 |
Completed |
GenePOC |
2017-08-02 |
| NCT00772343 |
Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFFâ„¢) in Subjects With Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT00772343 |
Completed |
Sanofi |
2011-07-31 |
| NCT00566306 |
Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation |
https://ClinicalTrials.gov/show/NCT00566306 |
Completed |
University of Helsinki |
2008-06-30 |
| NCT00563186 |
Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial |
https://ClinicalTrials.gov/show/NCT00563186 |
Completed |
University of Calgary |
2010-02-28 |
| NCT00468728 |
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT00468728 |
Completed |
Optimer Pharmaceuticals LLC |
2009-12-11 |
| NCT00417872 |
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis |
https://ClinicalTrials.gov/show/NCT00417872 |
Completed |
Romark Laboratories L.C. |
NA |
| NCT00382304 |
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT00382304 |
Completed |
Sanofi |
NA |
| NCT00350298 |
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease |
https://ClinicalTrials.gov/show/NCT00350298 |
Completed |
MassBiologics |
2008-07-31 |
| NCT00328263 |
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients |
https://ClinicalTrials.gov/show/NCT00328263 |
Completed |
Bio-K Plus International Inc. |
2007-03-31 |
| NCT00269399 |
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) |
https://ClinicalTrials.gov/show/NCT00269399 |
Completed |
Bausch Health Americas, Inc. |
2008-12-31 |
| NCT00214461 |
Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers |
https://ClinicalTrials.gov/show/NCT00214461 |
Completed |
Sanofi |
2006-02-28 |
| NCT00130221 |
Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections |
https://ClinicalTrials.gov/show/NCT00130221 |
Completed |
John H. Stroger Hospital |
NA |
| NCT00127803 |
Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers |
https://ClinicalTrials.gov/show/NCT00127803 |
Completed |
Sanofi |
2006-01-31 |
| NCT00034294 |
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT00034294 |
Completed |
Sanofi |
NA |
| NCT00314951 |
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) |
https://ClinicalTrials.gov/show/NCT00314951 |
Completed |
Optimer Pharmaceuticals LLC |
2008-07-23 |